Cost-effectiveness Study of Antihypertensive Drugs in Mumbai, India  by Limaye, D. et al.
S2 Abstract
Conclusions: These results suggest that an exercise (MIA and 
PRE) prescription for patients on HAART boosts their CD4 count. 
Importantly, CD4 count may be boosted more by MIA than by PRE 
exercises in patients on HAART and HAART-naive, respectively. The 
change factor suggests supports this conclusion and the effect size 
are of clinical significance.
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Background: Aldose reductase (AR) plays a pivotal role in the polyol 
pathway. In the diabetic condition, it is found to cause accumulation 
of polyol in lens fibers, causing influx of water and generation of 
osmotic stress leading to sugar cataracts. The objective of this study 
was to evaluate the AR inhibitory activity and anticataract activity of 
methanolic extract of Punica granatum Linn. fruit (MPGF).
Methods: AR inhibitory activity was evaluated in vitro in goat lenses. 
For the cataract model, goat lenses were incubated in artificial aque-
ous humor containing 55 mM of glucose with MPGF in different 
concentrations at room temperature for 72 hours. Opacification of 
the lens was assessed by counting the number of squares when placed 
over a graph paper, and biochemical parameters were estimated.
Results: MPGF exhibited in vitro AR inhibition activity with an 
IC50 of 300.43 (4.36) µg/mL. Glucose-induced opacification of the 
goat lens began 24 hours after incubation and was completed in 72 
hours. Cataractous lenses showed higher malondialdehyde and lower 
reduced glutathione, superoxide dismutase, and total proteins. Lenses 
treated with MPGF prevented formation and progress of cataract by 
glucose, as evidenced by biochemical parameters.
Conclusions: MPGF prevented cataract formation due to inhibition 
of the AR enzyme.
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Background: Hypertension is a serious global public health problem. 
It accounts for 10% of all deaths in India and is the leading noncom-
municable disease.1 Recent studies have shown that the prevalence 
of hypertension is 25% in urban and 10% in rural people in India.2 
It exerts a substantial public health burden on cardiovascular health 
status and health care systems in India.3 Antihypertensive treatment 
effectively reduces hypertension-related morbidity and mortality.1 
The cost of medications has always been a barrier to effective treat-
ment. The increasing prevalence of hypertension requires use of cost-
effective treatment for the effective management of the disease.
Objectives: The present study assesses the cost-effectiveness of anti-
hypertensive drugs in patients with hypertension from Mumbai, 
India.
Methods: A prospective cross-sectional study was conducted to 
assess the cost-effectiveness of antihypertensive drugs. Face-to-face 
interviews were conducted by using a validated questionnaire in a 
total of 136 (66 males, 70 females) patients with hypertension from 
F-North Ward, Mumbai, India. Cost-effectiveness was determined 
on the basis of a drug’s cost, efficacy, adverse drug reactions, safety 
of administration, frequency of administration, and bioavailability.
Results: Atenolol was most cost-effective (international normalized 
ratio [INR]: 5.5/unit of effectiveness), followed by the amlodipine 
+ losartan combination (INR: 5.6/unit of effectiveness) and amlodi-
pine (INR: 6.3/unit of effectiveness) in the present study. Thirty-eight 
(28%) patients received combination therapy. Lisinopril prescribed 
to16 (11.8%) patients was the least cost-effective drug (INR: 17.2/unit 
of effectiveness).
Conclusions: Prescriptions of cost-effective antihypertensive drugs 
(73.5%) were more common than less cost-effective antihypertensive 
drugs (26.5%) in hypertensive patients from Mumbai, India. Most 
of the patients (72%) were prescribed monotherapy in the treatment 
of hypertension.
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Background: Diabetes is fast gaining the status of a potential epi-
demic in India, with > 62 million individuals currently diagnosed 
with the disease.1 India currently faces an uncertain future in rela-
tion to the potential burden that diabetes may impose on the coun-
try. An estimated US$ 2.2 billion would be needed to sufficiently 
treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many 
interventions can reduce the burden of this disease. However, health 
care resources are limited; thus, interventions for diabetes treatment 
should be prioritized.
Objectives: The present study assesses the cost-effectiveness of anti-
diabetic drugs in patients with T2DM from Mumbai, India.
Methods: A prospective cross-sectional study was performed to 
assess the cost-effectiveness of antidiabetic drugs in patients with 
T2DM. Face-to-face interviews were conducted by using a validated 
questionnaire in a total of 152 (76 males, 76 females) patients with 
T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was 
determined on the basis of a drug’s cost, efficacy, adverse drug reac-
tions, safety of administration, frequency of administration, and 
bioavailability.
Results: The glimepiride plus pioglitazone combination was the 
most cost-effective (international normalized ratio [INR]: 3.7/unit 
of effectiveness), followed by glimepiride (INR: 6.6/unit of effective-
ness) prescribed in nonobese patients with T2DM. Glimepiride plus 
metformin was the most cost-effective (INR: 5.9/unit of effectiveness) 
followed by metformin (INR: 6.7/unit of effectiveness) prescribed in 
